Date:2/18/2009

f related debt during the year ended December 31, 2007, in conjunction with our financing arrangements. (h) A $3.9 million unrealized foreign currency loss associated with a cash escrow established in connection with the acquisition of BBI Holdings Plc, partially offset by a $1.9 million foreign currency gain realized on the settlement of intercompany notes. (i) A $1.7 million net realized foreign currency loss associated with a cash escrow established in connection with the acquisition of BBI Holdings Plc. (j) Tax effect on adjustments as discussed above in notes (b), (c), (d), (e), (f), (g), (h) and (i). (k) For the year ended December 31, 2008 and 2007, potential dilutive shares were not used in the calculation of diluted net loss per common share under GAAP because inclusion thereof would be antidilutive. (l) Included in the weighted average diluted common shares for the calculation of net income per common share for the year ended December 31, 2008, on an adjusted cash basis, are dilutive shares consisting of 2,188,000 common stock equivalent shares from the potential exercise of stock options and warrants and potential dilutive shares consisting of 3,411,000 common stock equivalent shares from the potential conversion of convertible debt securities. The diluted net income per common share calculation for the year ended December 31, 2008, on an adjusted cash basis, includes the add back of interest expense related to the convertible debt of $2.8 million resulting in net income available to common stockholders of $164.0 million. Potential dilutive shares consisting of 6,681,000 common stock equivalent shares from the potential conversion of Series B convertible preferred stock for the year ended December 31, 2008 w
'/>"/>

SOURCE Inverness Medical Innovations, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
Related medicine news :

1. Inverness Medical Innovations Schedules Conference Call for 10:00 a.m. ET February 18, 2009 to Discuss Fourth Quarter 2008 Results
2. James Roosevelt, Jr. Joins Inverness Medical Innovations Board of Directors
3. Inverness Medical Innovations to Present at the 2009 UBS Global Healthcare Services Conference on February 10, 2009
4. Inverness Medical Innovations Presents the pima(TM) Point-of-Care CD4 Instrument at ICASA 2008
5. Inverness Medical Innovations to Participate at JP Morgan Healthcare Conference on January 13, 2009
6. Inverness Medical Innovations Declares Dividend on its Series B Convertible Perpetual Preferred Stock
7. Inverness Medical Innovations to Present at RBC Capital Markets 2008 Healthcare Conference on December 11, 2008
8. Inverness Medical Innovations, PrognostiX Sign Distribution Agreement for CardioMPO(TM) Test
9. Inverness Medical Innovations to Present at the Third Annual JMP Securities Healthcare Focus Conference on October 7, 2008
10. Inverness Medical Innovations Announces 4th Generation Rapid HIV Test - Determine(TM) HIV-1/2 Ag/Ab Combo
11. Law Offices of Howard G. Smith Announces 24 Days Remaining to Move to Be a Lead Plaintiff in the Shareholder Lawsuit Against Inverness Medical Innovations, Inc.